Cargando…
After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite the use o...
Autores principales: | Evora, Paulo Roberto B., Soares, Ricardo O. S., Bassetto, Solange, Martins, Maria Auxiliadora, Silva, Fábio Luis da Silva, Basile Filho, Anibal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cirurgia Cardiovascular
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357386/ https://www.ncbi.nlm.nih.gov/pubmed/34387976 http://dx.doi.org/10.21470/1678-9741-2021-0955 |
Ejemplares similares
-
Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene
blue revised
por: Evora, Paulo Roberto Barbosa, et al.
Publicado: (2015) -
Methylene Blue for Vasoplegic Syndrome Postcardiac Surgery
por: Habib, Aly Makram, et al.
Publicado: (2018) -
Why Methylene Blue Is the Only Option for Blocking the cGMP/NO Pathway in The Treatment of Vasoplegic Shock? “Reasons That Reason Itself Does Not Know...”
por: Evora, Paulo Roberto B., et al.
Publicado: (2021) -
Methylene Blue For Post-Cardioplumonary Bypass Vasoplegic Syndrome
por: Pangasa, Neha, et al.
Publicado: (2017) -
Methylene Blue for Postcardiopulmonary Bypass Vasoplegic Syndrome: A Cohort Study
por: Mazzeffi, Michael, et al.
Publicado: (2017)